Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

I
1149
Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel
Pathogenesis of CLL

Favorite
1209
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Therapy of CLL

Favorite
1001
Identification of novel targets that upregulate CD20 expression in rituximab-resistant cells with the use of genome-wide CRISPR screening
Clinical Challenges in CLL

Favorite
1111
Immune-profiling of ibrutinib-treated CLL patients revealed TMBIM6 as a potential target for CLL and its high expression as an independent variable associated with poor prognosis
Pathogenesis of CLL

Favorite
1009
IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4
Pathogenesis of CLL

Favorite
1030
Immunophenotypic Characterization of Richter Syndrome Diffuse Large B-Cell Lymphoma Type and Comparison with the Original Chronic Lymphocytic Leukemia
Clinical Challenges in CLL

Favorite
1112
Immunophenotyping of Chronic Lymphocytic Leukemia in Yemen.
Past, Present, and Future in CLL

Favorite
1201
Impact of COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: a possible role of the association to anti-CD20 antibody? A multicentre SEIFEM study.
Past, Present, and Future in CLL

Favorite
2006
Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression
Pathogenesis of CLL

Favorite
1049
Impact of T-cell co-stimulatory molecule CLECL1 expressing CLL cells on CLL disease progression and transformation to Richter's syndrome
Pathogenesis of CLL

Favorite
1154
Impaired long-term antibody persistence after primary immunization with pneumococcal vaccines in patients with chronic lymphocytic leukemia compared to immunocompetent controls
Past, Present, and Future in CLL

Favorite
1024
Impaired mitochondrial metabolism drives T-cell dysfunction in chronic lymphocytic leukemia
Pathogenesis of CLL

Favorite
1146
Implementing the data-driven CLL-TIM algorithm into an EPIC-based EHR: proof of concept for automated decision support models
Past, Present, and Future in CLL

Favorite
1129
Incidence and clinical correlates of non-immune cytopenia at diagnosis of chronic lymphocytic leukemia
Past, Present, and Future in CLL

Favorite
1224
Incidence of arrhythmia in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib: a real-world retrospective analysis from two Italian centers.
Past, Present, and Future in CLL

Favorite
1051
Increased susceptibility to Streptococcus pneumoniae pulmonary infection in the Eµ-TCL1 adoptive transfer mouse model of CLL
Pathogenesis of CLL

Favorite
1011
In-depth molecular analysis using a multi-gene lymphoma NGS panel in lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis, differentiation of entities and may optimize rational treatment allocations
Pathogenesis of CLL

Favorite
1038
Inhibition of G protein-coupled receptor kinase 2 (GRK2) as a strategy to modulate leukemic cell homing and activation in CLL
Pathogenesis of CLL

Favorite
1139
Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Therapy of CLL

Favorite
1102
Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Clinical Challenges in CLL

Favorite